{
    "id": "nclex_bowtie_2026_001",
    "questionType": "bowtie",
    "question": "The nurse is caring for a 68-year-old client in the emergency department who presented 90 minutes ago with acute onset of aphasia and right-sided hemiparesis. The stroke team has been activated, and an order for intravenous alteplase (tPA) is in the Medication Administration Record (MAR). The nurse has gathered the following data.",
    "prompt": "Complete the diagram by dragging the choices from the lists to the spaces provided. Based on the client's data, the nurse should identify the client is at highest risk for developing **[1]**. Therefore, the nurse should perform the actions of **[2]** and **[3]** while closely monitoring the client's **[4]** and **[5]**.",
    "tabs": [
        {
            "title": "Nurses' Notes",
            "content": "08:00: Client arrives via private vehicle. Spouse reports client suddenly developed slurred speech and right arm/leg weakness while eating breakfast. Last known well time was 06:30. Client has a history of hypertension (HTN) and atrial fibrillation, but spouse states client is 'not great' about taking his medications. NIH Stroke Scale (NIHSS) score is 16, indicating a moderate to severe stroke.\n\n08:15: Non-contrast head CT completed.\n\n08:30: Initial BP 205/112 mmHg. Labetalol 10 mg IV push administered as per stroke protocol.\n\n08:45: Client remains drowsy but arousable, follows commands with left side only. Aphasia and right hemiplegia unchanged."
        },
        {
            "title": "Vital Signs",
            "content": {
                "type": "table",
                "headers": [
                    "Time",
                    "BP (mmHg)",
                    "HR (bpm)",
                    "RR (breaths/min)",
                    "SpO2 (%)",
                    "Temp (°C)"
                ],
                "rows": [
                    [
                        "08:00 (Arrival)",
                        "205/112",
                        "98 (irregular)",
                        "18",
                        "96%",
                        "37.1"
                    ],
                    [
                        "08:15",
                        "200/110",
                        "95 (irregular)",
                        "18",
                        "97%",
                        "37.1"
                    ],
                    [
                        "08:30",
                        "205/112",
                        "101 (irregular)",
                        "16",
                        "96%",
                        "37.2"
                    ],
                    [
                        "08:45",
                        "198/108",
                        "96 (irregular)",
                        "16",
                        "97%",
                        "37.2"
                    ]
                ]
            }
        },
        {
            "title": "Laboratory Results",
            "content": {
                "type": "table",
                "headers": [
                    "Test",
                    "Result",
                    "Reference Range"
                ],
                "rows": [
                    [
                        "Glucose, Point-of-Care",
                        "155 mg/dL",
                        "70-110 mg/dL"
                    ],
                    [
                        "INR",
                        "1.3",
                        "0.8-1.2"
                    ],
                    [
                        "Platelet Count",
                        "220,000/mm³",
                        "150,000-450,000/mm³"
                    ],
                    [
                        "Creatinine",
                        "1.0 mg/dL",
                        "0.6-1.2 mg/dL"
                    ],
                    [
                        "Troponin I",
                        "<0.03 ng/mL",
                        "<0.04 ng/mL"
                    ]
                ]
            }
        },
        {
            "title": "Diagnostic Results",
            "content": "**Non-Contrast Head CT Report:**\n\nFINDINGS: No evidence of acute intracranial hemorrhage, mass effect, or hydrocephalus. Age-related cerebral volume loss is noted. There are subtle signs of early ischemia in the left middle cerebral artery (MCA) territory."
        },
        {
            "title": "MAR",
            "content": {
                "type": "table",
                "headers": [
                    "Medication",
                    "Dose",
                    "Route",
                    "Frequency",
                    "Status"
                ],
                "rows": [
                    [
                        "Alteplase (tPA)",
                        "Per stroke protocol",
                        "IV",
                        "STAT",
                        "Pending"
                    ],
                    [
                        "Labetalol",
                        "10 mg",
                        "IV Push",
                        "Once",
                        "Administered at 08:30"
                    ],
                    [
                        "Normal Saline",
                        "75 mL/hr",
                        "IV",
                        "Continuous",
                        "Running"
                    ]
                ]
            }
        }
    ],
    "options": {
        "potentialCondition": [
            {
                "id": "pc1",
                "label": "Hemorrhagic conversion secondary to uncontrolled hypertension"
            },
            {
                "id": "pc2",
                "label": "Cardioembolic stroke progression"
            },
            {
                "id": "pc3",
                "label": "Acute kidney injury"
            },
            {
                "id": "pc4",
                "label": "Anaphylactic reaction to alteplase"
            },
            {
                "id": "pc5",
                "label": "Neurogenic shock"
            }
        ],
        "actionsToTake": [
            {
                "id": "a1",
                "label": "Withhold administration of alteplase"
            },
            {
                "id": "a2",
                "label": "Notify the provider of the refractory hypertension"
            },
            {
                "id": "a3",
                "label": "Administer the alteplase bolus immediately"
            },
            {
                "id": "a4",
                "label": "Request an order for an additional diuretic"
            },
            {
                "id": "a5",
                "label": "Place the client in a Trendelenburg position"
            }
        ],
        "parametersToMonitor": [
            {
                "id": "p1",
                "label": "Blood pressure"
            },
            {
                "id": "p2",
                "label": "Neurological status"
            },
            {
                "id": "p3",
                "label": "INR trend"
            },
            {
                "id": "p4",
                "label": "Urine output"
            },
            {
                "id": "p5",
                "label": "Heart rhythm on telemetry"
            }
        ]
    },
    "correctAnswer": {
        "potentialCondition": "pc1",
        "actionsToTake": [
            "a1",
            "a2"
        ],
        "parametersToMonitor": [
            "p1",
            "p2"
        ]
    },
    "rationale": {
        "correct": "The central clinical problem is that the client's blood pressure remains persistently elevated above the mandatory threshold of 185/110 mmHg for safe alteplase administration. Despite receiving IV labetalol, the BP at 08:45 is 198/108 mmHg. Administering a thrombolytic agent to a client with uncontrolled hypertension dramatically increases the risk of converting the ischemic stroke into a life-threatening intracerebral hemorrhage. The nurse's primary responsibility is to recognize this absolute contraindication ('SAFETY STOP'), withhold the medication, and immediately notify the provider to facilitate further BP management before the tPA window closes.",
        "incorrect": "The incorrect options represent actions that are either dangerous, not indicated, or not the priority. Administering alteplase would be a catastrophic error. Focusing on INR (which is acceptable), urine output, or heart rhythm misses the immediate, life-threatening contraindication presented by the vital signs trend. Placing the client in Trendelenburg is contraindicated as it can increase intracranial pressure. Requesting a diuretic is not the nurse's independent role and may not be the provider's choice for acute BP management in this scenario.",
        "answerBreakdown": [
            {
                "label": "Hemorrhagic conversion secondary to uncontrolled hypertension",
                "content": "This is the correct condition. The primary risk of administering alteplase when the BP is >185/110 mmHg is inducing a bleed in the damaged cerebral vasculature. The uncontrolled pressure creates a high-flow, high-pressure state in fragile vessels, and adding a fibrinolytic agent that dissolves clots systemically can lead to catastrophic intracerebral hemorrhage.",
                "isCorrect": true
            },
            {
                "label": "Withhold administration of alteplase",
                "content": "This is a correct and critical safety action. Current guidelines establish a BP of >185/110 mmHg as an absolute contraindication for alteplase. The nurse must recognize from the vital signs trend that the initial dose of labetalol was ineffective and that the BP remains in the danger zone. Proceeding would be a violation of safety protocols.",
                "isCorrect": true
            },
            {
                "label": "Notify the provider of the refractory hypertension",
                "content": "This is a correct and essential communication action. The nurse cannot independently order more antihypertensives. The provider must be made aware that the BP has not responded to the initial intervention so that a different agent (e.g., nicardipine drip) or additional doses can be ordered and administered promptly in an attempt to lower the BP to a safe level before the 4.5-hour tPA window closes.",
                "isCorrect": true
            },
            {
                "label": "Blood pressure",
                "content": "This is a correct parameter to monitor. It is the single most critical vital sign in this scenario, as it is the sole contraindication currently preventing a time-sensitive, potentially life-saving treatment. Frequent and accurate BP monitoring is essential to guide further therapy and determine if/when alteplase can be safely given.",
                "isCorrect": true
            },
            {
                "label": "Neurological status",
                "content": "This is a correct parameter to monitor. The nurse must continuously assess for any deterioration in the client's neurological status (e.g., decreased level of consciousness, pupillary changes, worsening motor function, sudden severe headache). Such changes could indicate increasing intracranial pressure or an evolving hemorrhage, even before tPA is given.",
                "isCorrect": true
            },
            {
                "label": "Cardioembolic stroke progression",
                "content": "Incorrect. While the client's atrial fibrillation suggests a cardioembolic source, and the stroke is progressing, the most immediate, iatrogenic risk the nurse must prevent is hemorrhagic conversion from giving tPA with uncontrolled HTN. This option describes the pathophysiology of the stroke, not the immediate risk of the proposed intervention.",
                "isCorrect": false
            },
            {
                "label": "Acute kidney injury",
                "content": "Incorrect. The client's creatinine is within the normal range, and there is no data to suggest an acute kidney injury is the primary problem.",
                "isCorrect": false
            },
            {
                "label": "Anaphylactic reaction to alteplase",
                "content": "Incorrect. This is a potential risk *after* the medication is administered, but the current data indicates the medication should not be given at all. The priority is identifying contraindications *before* administration.",
                "isCorrect": false
            },
            {
                "label": "Neurogenic shock",
                "content": "Incorrect. Neurogenic shock is characterized by hypotension and bradycardia, typically seen with spinal cord injuries. This client is severely hypertensive and tachycardic, which is the opposite clinical picture.",
                "isCorrect": false
            },
            {
                "label": "Administer the alteplase bolus immediately",
                "content": "Incorrect. This is a life-threatening action. Administering alteplase while the blood pressure is >185/110 mmHg is a direct violation of established safety protocols and places the client at extremely high risk for intracerebral hemorrhage.",
                "isCorrect": false
            },
            {
                "label": "Request an order for an additional diuretic",
                "content": "Incorrect. While BP management is needed, diuretics are generally not the first-line agents for acute, severe hypertension in a stroke setting. The nurse's role is to report the refractory hypertension, not to suggest a specific, and potentially less effective, medication class.",
                "isCorrect": false
            },
            {
                "label": "Place the client in a Trendelenburg position",
                "content": "Incorrect. This position is contraindicated as it increases blood flow to the head, which can raise intracranial pressure (ICP) in a client with an acute stroke.",
                "isCorrect": false
            },
            {
                "label": "INR trend",
                "content": "Incorrect. The initial INR is 1.3, which is below the contraindication threshold of >1.7. While it was an important value to check initially, it is not the dynamic parameter that is currently preventing treatment. The BP is the critical, unstable variable.",
                "isCorrect": false
            },
            {
                "label": "Urine output",
                "content": "Incorrect. While important for assessing overall hemodynamic stability and renal perfusion, it is not as critical as blood pressure and neurological status in the immediate decision-making process regarding alteplase administration.",
                "isCorrect": false
            },
            {
                "label": "Heart rhythm on telemetry",
                "content": "Incorrect. The client is known to have atrial fibrillation, which is noted on the heart rate reading. While continuous monitoring is standard, the atrial fibrillation itself is not a contraindication for tPA, and it is not the parameter that is actively preventing treatment at this moment. The BP is the critical issue.",
                "isCorrect": false
            }
        ]
    },
    "pedagogy": {
        "bloomLevel": "Evaluating",
        "cjmmStep": "Analyze Cues",
        "nclexCategory": "Reduction of Risk Potential",
        "nclexSubcategory": "Potential for Complications of Diagnostic Tests/Treatments/Procedures",
        "difficulty": "Hard",
        "topicTags": [
            "Ischemic Stroke",
            "Alteplase",
            "tPA",
            "Contraindication",
            "Hypertension",
            "Patient Safety",
            "Pharmacology"
        ]
    }
}